• Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
    • Our Company
      • Therapeutics
      • Precision Medicine
      • MedTech
      • Telix Manufacturing Solutions
    • Our Technology
    • Partnering with Telix
    • Board & Management
    • Sustainability
  • Our Portfolio and Pipeline
    • Disease Areas
      • Urologic Oncology
      • Neurologic Oncology
      • Other Tumors
    • Our Pipeline
    • Our Portfolio
    • Research & Development
  • Clinical Trials
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a Job
  • Our Company
  • Our Portfolio
  • Investor Center
  • News & Views
  • Careers
  • Contact Us
  • Telix Hotline
  • Legal Notices

Subscribe to our newsletter to stay in the loop

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.​
The Telix Pharmaceuticals, the Illuccix and Gozellix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.​
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.​

  • Privacy Policy
  • Terms of Use
  • Cookies Policy
  • Consumer Health Privacy Notice
  • Privacy Settings

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”